LEO Pharma

137 articles about LEO Pharma

• LEO Pharma to Acquire Peplin Inc. for $287.5 Million

  9/3/2009

• 2008 Record Financial Statements from LEO Pharma

  3/27/2009

• LEO Pharma Wins a Litigation with Generic Drug Manufacturer Kotra Pharma in Malaysia

  1/23/2009

• LEO Pharma Establishes Strategic Company in China, LEO Pharma China

  12/8/2008

• LEO Pharma Unveils Major Breakthrough in Psoriasis Management

  9/22/2008

• Xamiol(R) - LEO Pharma's New Drug for the Treatment of Scalp Psoriasis - is Approved in Europe

  8/19/2008

• LEO Pharma Goes Live on Oracle Remote Data Capture

  6/24/2008

• LEO Pharma: ATryn(R) - A Safe Drug Without Use of Donor Blood

  11/26/2007

• Warner Chilcott and LEO Pharma Announce NDA Submission for Taclonex Scalp(R) Gel

  7/2/2007

• GTC Biotherapeutics Release: ATryn® Market Authorization Transferred To LEO Pharma A/S

  1/3/2007

• LEO Pharma And Warner Chilcott Announce Receipt Of Paragraph IV Certification Notice For Dovonex(R) Solution

  6/29/2006

• GTC Biotherapeutics Receives $1 Million Milestone Payment From LEO Pharma

  6/14/2006

• Warner Chilcott And LEO Pharma Release: Taclonex(R) New Dual-Action Topical Therapy For Plaque Psoriasis Now Available For Prescription

  4/3/2006

• FDA Approves Warner Chilcott's And LEO Pharma's Taclonex(R) - Once Daily Therapy For Treatment Of Psoriasis

  1/10/2006

• Elsevier MDL Release: MDL Isentris Platform Selected By LEO Pharma

  12/21/2005

• GTC Biotherapeutics And LEO Pharma To Develop And Market ATryn(R) In Europe, The Middle East, And Canada; $70M Development Deal

  11/1/2005

• Alliance Pharmaceutical Corp. And LEO Pharma Modify Exclusivity Agreement Related To The Development And Marketing Of Oxygent((TM) In Europe And Canada

  3/2/2005